BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Townsend AR, Bishnoi S, Broadbridge V, Beeke C, Karapetis CS, Jain K, Luke C, Padbury R, Price TJ. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013;36:49-52. [PMID: 22270106 DOI: 10.1097/COC.0b013e31823fe40e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Kim KR, Yoon JH, Shim HJ, Hwang JE, Bae WK, Chung IJ, Kim HN, Shin MH, Cho SH. Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer. Oncol Lett 2017;14:2491-8. [PMID: 28781687 DOI: 10.3892/ol.2017.6414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Argyriou AA. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN). Toxics 2015;3:187-97. [PMID: 29056657 DOI: 10.3390/toxics3020187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
3 Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. Target Oncol 2017;12:525-33. [PMID: 28669023 DOI: 10.1007/s11523-017-0505-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
4 Papadimitriou K, Rolfo C, Dewaele E, Van De Wiel M, Van den Brande J, Altintas S, Huizing M, Specenier P, Peeters M. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer. Curr Treat Options Oncol 2015;16:18. [PMID: 25813037 DOI: 10.1007/s11864-015-0333-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Chambers AE, Frick J, Tanner N, Gerkin R, Kundranda M, Dragovich T. Chemotherapy re-challenge response rate in metastatic colorectal cancer. J Gastrointest Oncol 2018;9:679-86. [PMID: 30151264 DOI: 10.21037/jgo.2018.04.08] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Reddy TP, Khan U, Burns EA, Abdelrahim M. Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review . World J Clin Oncol 2020; 11(11): 959-967 [PMID: 33312889 DOI: 10.5306/wjco.v11.i11.959] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fernandes GDS, Braghiroli MI, Artioli M, Paterlini ACCR, Teixeira MC, Gumz BP, Girardi DDM, Braghiroli OFM, Costa FP, Hoff PM. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. J Gastrointest Cancer 2018;49:470-5. [PMID: 28884286 DOI: 10.1007/s12029-017-0001-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kawagoe T, Ikeda G, Oshiro Y, Maruki Y, Kaneko K, Iwakiri K. Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer. Case Rep Oncol Med 2020;2020:2351810. [PMID: 32655959 DOI: 10.1155/2020/2351810] [Reference Citation Analysis]
9 Hata A, Katakami N, Fujita S, Takatori K, Horai A, Kitajima N, Terashima K. Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer. J Gastrointest Cancer 2013;44:456-9. [PMID: 23212286 DOI: 10.1007/s12029-012-9453-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
10 Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2021;127:1417-24. [PMID: 33351187 DOI: 10.1002/cncr.33379] [Reference Citation Analysis]